Abstract
Mesenchymal stromal cells (MSCs) have unique immunomodulatory capacities. We investigated hair follicle-derived MSCs (HF-MSCs) from the dermal sheath, which are advantageous as an alternative source because of their relatively painless and minimally risky extraction procedure. These cells expressed neural markers upon isolation and maintained stemness for a minimum of 10 passages. Furthermore, HF-MSCs showed responsiveness to pro-inflammatory environments by expressing type-II major histocompatibility complex antigens (MHC)-II to a lesser extent than adipose tissue-derived MSCs (AT-MSCs). HF-MSCs effectively inhibited the proliferation of peripheral blood mononuclear cells equivalently to AT-MSCs. Additionally, HF-MSCs promoted the induction of CD4+CD25+FOXP3+ regulatory T cells to the same extent as AT-MSCs. Finally, HF-MSCs, more so than AT-MSCs, skewed M0 and M1 macrophages towards M2 phenotypes, with upregulation of typical M2 markers CD163 and CD206 and downregulation of M1 markers such as CD64, CD86, and MHC-II. Thus, we conclude that HF-MSCs are a promising source for immunomodulation.
Highlights
Mesenchymal stromal cells (MSCs) are proliferative and multipotent cells that exist in most tissues of the body and show numerous therapeutic properties
We evaluated the capacity of hair follicle-derived MSCs (HF-MSCs) to induce T regulatory differentiation as compared to adipose tissue-derived MSCs (AT-MSCs)
HFMSCs showed immunomodulatory potential equal to or exceeding that of AT-MSCs, inMSCs showed immunomodulatory potential equal to or exceeding that of AT-MSCs, includcluding inhibition of peripheral blood mononuclear cells (PBMCs) proliferation, suppression of cytotoxic T cell induction, proing inhibition of PBMC proliferation, suppression of cytotoxic T cell induction, promotion motion of regulatory T cell differentiation, and modulation of macrophage phenotype of regulatory T cell differentiation, and modulation of macrophage phenotype from M1 to from M1 to M2. These results suggest that HF-MSCs should be considered a viable alterM2. These results suggest that HF-MSCs should be considered a viable alternative to BMnative to BM- and AT-MSCs for therapies that rely on their immunomodulatory potential
Summary
Mesenchymal stromal cells (MSCs) are proliferative and multipotent cells that exist in most tissues of the body and show numerous therapeutic properties As their immunomodulatory potential has become increasingly appreciated through hundreds of clinical trials—reviewed in [1]—in recent years, a number of MSC cell therapies have been approved for clinical use, including Temcell® , Alofisel® , and Remestemcel-L—reviewed in [1,2]. MSCs have two important characteristics that make them an attractive therapeutic option for a wide range of inflammatory and immune-mediated diseases: immune evasion and immunomodulation. Their ability to evade immune rejection results from relatively 4.0/). The clinical potential of MSCs remains limited by numerous obstacles, including (i) the invasive and painful harvesting procedure with possible complications; (ii) their gradual loss of “stemness” and immunomodulatory properties during in vitro expansion; and (iii) their loss of immune evasiveness in inflammatory environments [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
